Sera from patients with malignant mesothelioma can contain autoantibodies

Lung Cancer

Volumn 20, Issue 3, 1998, Pages 175-184

  Robinson, Cleo ^a   Robinson, Bruce W S ^a   Lake, Richard A ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Autoantibodies; Malignant mesothelioma; Tissue specificity; Tumor associated antigens; Western blot

Indexed keywords

AUTOANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; AUTOANTIBODIES; BLOTTING, WESTERN; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; TISSUE DISTRIBUTION;

EID: 0031822966     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00014-2     Document Type: Article

References (34)

1. Ruffie P. Pleural mesothelioma. Curr Opin Oncol. 4:1992;334-341.
2. Anderson HA, Hanrahan LP, Schirmer J, Higgins D, Sarow P. Mesothelioma among employees with likely contact with in-place asbestos-containing building materials. Ann NY Acad Sci 1991;550-72.
3. Robinson B.W.S. Development of new therapeutic strategies for mesothelioma. Lung Cancer. 9:1993;413-418.
4. Christmas T, Manning L, Garlepp M, Musk A, Robinson B. Effect of Interferon alpha-2a on malignant mesothelioma. J Interferon Res 1992;9-12.
5. Robinson B., Bowman R., Manning L., Musk A., van Hazel G. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma. Eur Respir Rev. 3:1993;220-222.
6. Upham J., Musk A., van Hazel G., Byrne M., Robinson B. Interferon alpha and doxorubicin in malignant mesothelioma. Aust New Zealand J Med. 23:1993;683-687.
7. Davis M.R., Manning L.S., Whitaker D., Garlepp M.J., Robinson B.W. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 52:1992;881-886.
8. Bielefeldt O.H., Fitzpatrick D.R., Marzo A.L., Jarnicki A.G., Himbeck R.P., Davis M.R., Manning L.S., Robinson B.W. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother. 39:1994;347-359.
9. Leong C.C., Robinson B.W., Garlepp M.J. Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. Int J Cancer. 59:1994;212-216.
10. Bielefeldt O.H., Marzo A.L., Himbeck R.P., Jarnicki A.G., Robinson B.W., Fitzpatrick D.R. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother. 40:1995;241-250.
11. Garlepp M.J., Leong C.C. Biological and immunological aspects of malignant mesothelioma. Eur Respir J. 8:1995;643-650.
12. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:1996;136-140.
13. Donna A., Betta P.G., Cosimi M.F., Robutti F., Bellingeri D., Marchesini A. Putative mesothelial cell growth-promoting activity of a cytoplasmic protein expressed by the mesothelial cell. A preliminary report. Exp Cell Biol. 57:1989;193-197.
14. Boon T., Cerottini J.C., Vandeneynde B., Vanderbruggen P., Vanpel A. Tumour antigens recognized by T lymphocytes. Ann Rev Immunol. 12:1994;337-365.
15. Pardoll D.M. Tumour antigens - a new look for the 1990s. Nature. 369:1994;357-358.
16. Paglia P., Chiodoni C., Rodolfo M., Colombo M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumour antigen in vivo. J Exp Med. 183:1996;317-322.
17. Brichard V., Van P.A., Wolfel T., Wolfel C., De P.E., Lethe B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 178:1993;489-495.
18. Coulie P.G., Brichard V., Van P.A., Wolfel T., Schneider J., Traversari C., Mattei S., De P.E., Lurquin C., Szikora J.P.et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. J Exp Med. 180:1994;35-42.
19. Haraguchi M., Yamashiro S., Yamamoto A., Furukawa K., Takamiya K., Lloyd K.O., Shiku H., Furukawa K. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc Natl Acad Sci USA. 91:1994;10455-10459.
20. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., Miki T., Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc Natl Acad Sci USA. 91:1994;3515-3519.
21. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., Appella E., Rosenberg S.A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumour infiltrating lymphocytes. J Exp Med. 180:1994;347-352.
22. Salgaller M.L., Weber J.S., Koenig S., Yannelli J.R., Rosenberg S.A. Generation of specific anti-melanoma reactivity by stimulation of human tumour-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother. 39:1994;105-116.
23. Manning L.S., Whitaker D., Murch A.R., Garlepp M.J., Davis M.R., Musk A.W., Robinson B.W. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer. 47:1991;285-290.
24. Old L.J. Cancer immunology: the search for specificity - G.H.A. Clowes Memorial Lecture [Review]. Cancer Res. 41:1981;361-375.
25. Noguchi Y., Chen Y.T., Old L.J. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA. 91:1994;3171-3175.
26. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52:1992;6380-6384.
27. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:1995;11810-11813.
28. De Plaen E., Lurquin C., Van Pel A., Mariame B., Szikora J.P., Wolfel T., Sibille C., Chomez P., Boon T. Immunogenic (tum-) variants of mouse tumour P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc Natl Acad Sci USA. 85:1988;2274-2278.
29. Van Bleek G., Nathenson S.G. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule [see comments]. Nature. 348:1990;213-216.
30. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 351:1991;290-296.
31. Roth C., Rochlitz C., Kourilsky P. Immune response against tumours. Adv Immunol. 57:1994;281-351.
32. Fitzpatrick D.R., Bielefeldt Ohmann H., Himbeck R.P., Jarnicki A.G., Marzo A.L., Robinson B.W. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumourigenicity and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors. 11:1994;29-44.
33. Carbone F.R., Bevan M.J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med. 171:1990;377-387.
34. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumour antigens. 1994;264:961-65.